Patient Highlights from the 2024 ASCO GU conference
In a 75-minute “pre-game” before the 2/27/2024 meeting of the high-risk/recurrent/advanced prostate cancer group, moderators John, Rick, Ben, and Len discussed highlights from the just-concluded ASCO GU conference, a major meeting for genitourinary cancer specialists. They selected from hundreds of papers on prostate cancer presented in sessions and posters. We closed with a 30-minute audience Q&A.
What we covered:
- Abi boosts olaparaib for BRCA
- After triplet therapy, what next?
- Less treatment, same cancer-fighting power
- Trial of a neuroendocrine PCa drug
- Prostate cancer and suicide
- Germline & somatic testing is too infrequent
- What treatments work after Pluvicto
- Pluvicto flare largely lasts only one treatment
- Community providers do poor job treating mCSPC men
- Increased risk of a second cancer
- Mixed evidence on concordance scans
- Tumor growth without PSA rise
- Toxicity/benefit tradeoffs for patients
- Importance of PSMA PET Scan Concordance
- APA PSA90 Better than ENZA in mHSPC?
- APA PSA90 Better than ABI in mHSPC?
- What’s the best prednisone dose with ABI?
- OS based on the site of metastases
- Paradigm for Sequencing PARPi with Lu-PSMA?
The evening’s slides are available at https://drive.google.com/file/d/18bH04PnXNEuKLmGLAq4aVHzDEzdSl1pf/view?usp=sharing